Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB204 cutaneous effects in healthy volunteers
NCT02250430Phase 1Completed
- Sponsor
- Novan
- Start
- Sep 2014
- Primary completion
- Sep 2014
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of berdazimer in acne vulgaris, sponsored by Novan. Primary endpoints: Intensity of erythema at 3 days and Duration of erythema at 3 days. Started Sep 2014; status: completed.
02
Drugs
berdazimer
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02250430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250430.